Amgen Inc. reported better-than-expected first-quarter results even as some newer drugs that analysts expect to drive growth over the next few years underperformed.

Amgen (NASDAQ:AMGN) executives said the company delivered a “strong first quarter” and remains positioned to meet its goals ...

By Deena Beasley April 30 (Reuters) - Amgen on Thursday said its first-quarter product sales rose 4%, helped by demand for ...

The FDA’s real-time clinical trial mechanism allows drug sponsors to transmit data immediately to the regulator through the ...

The biotechnology company reported a profit of $1.82 billion, driven by a 4% rise in product sales.

AMGN) on Thursday reported first-quarter profit of $1.82 billion. On a per-share basis, the Thousand Oaks, California-based company said it had profit of $3.34. Earnings, adjusted for non-recurring ...

The FDA has renewed calls for Amgen’s Tavneos to be pulled from the market, saying it has discovered new evidence that study ...

Regeneron Pharmaceuticals Inc. asked a federal judge to require Amgen Inc. to turn over damages evidence for antitrust ...

The US Food and Drug Administration (FDA) is launching a pilot to implement real-time clinical trials (RTCT). While ...

Novartis, Amgen and Eli Lilly are betting that slashing levels of a particularly bad form of cholesterol could deliver the ...

The FDA today announced a new initiative to allow its reviewers to access information from clinical trials in real time, with ...